ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Pumpkin Pie Turmeric Breakfast Smoothie - Vegan + Gluten-Free

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Vitamin D supplementation extends life in mouse model of Huntington's disease

Omega-3 fatty acid stops known trigger of lupus

Conquer Your Email Inbox, Increase Productivity and Reduce Stress

The Significance of Selenium

Print Page
Email Article

Potential Anti-Cancer Agent Being Developed from Anti-Inflammation Drug

  [ 20 votes ]   [ Discuss This Article ] • July 8, 2004

Source: Cancer Research (journal) COLUMBUS, Ohio – Researchers have used a recently developed anti-inflammatory drug as a starting point to construct a possible new, targeted anti-cancer agent. The new agent works by triggering cancer cells to self-destruct. The agent is now undergoing laboratory testing by the National Cancer Institute’s (NCI) Rapid Access to Intervention Development (RAID) program. The potential new drug was developed by researchers at The Ohio State University College of Pharmacy and the OSU Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Presently, the agent is known as OSU-03012. The study is published in the June 15 issue of the journal Cancer Research. “This new agent works by inhibiting a fundamental signaling point in cancer cells, making it potentially effective in a wide range of cancer types,” says study leader Ching-Shih Chen, professor of pharmacy and a researcher with OSU’s Comprehensive Cancer Center. “We also have evidence that it may sensitize leukemia, and breast and lung cancers to conventional chemotherapy.” The new agent is based on the drug celecoxib, a nonsteroidal anti-inflammatory drug, or NSAID. Like many NSAIDs, celecoxib also reduces the risk of colorectal cancer when taken regularly. Scientists knew from the start that celecoxib helps control inflammation by inhibiting an enzyme known as cyclooxygenase-2 (COX-2). But they couldn’t explain the drug’s modest anti-cancer activity. Past work led by Chen provided the answer. “We found that celecoxib’s ability to cause cell death and to control inflammation were two different pharmacological properties, and that the two properties could be separated,” Chen says. This work was published in the Journal of the National Cancer Institute. Chen and his colleagues then showed that celecoxib inhibited a molecule known as Akt. Chen describes Akt as an important molecular switch that transmits information from the cell surface down into the cell to interact with a variety of target molecules. He and colleagues further found that the blocking of Akt by celecoxib in cancer cells triggered programmed cell death, a process also known as apoptosis. For this study, Chen and his colleagues used molecular-modeling methods and computational chemistry to alter celecoxib’s basic molecular structure in ways calculated to maximize its Akt-blocking and cell-death inducing activities. This work generated a series of derivative molecules, all of which were far different in structure from celecoxib. Two of these proved to be 30 to 50 times more potent than celecoxib in inducing programmed cell death in cancer cells growing in the laboratory tests. One of the derivatives, OSU 03012, is now undergoing toxicological and pharmacological testing by the NCI’s RAID program. Data from these tests will help move the agent forward into human testing in a phase I clinical trial, probably within one to two years. Funding from the National Cancer Institute and the Department of Defense Prostate Cancer Research Program supported this research. Source: (this is a press release).

Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength Mitochondria Ignite™ with NT Factor® FibroSleep™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Natural Pain Relief Supplements

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

More Weight Loss than Any Other Discovery in Supplement History More Weight Loss than Any Other Discovery in Supplement History
Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial
Natural Relief for Soreness, Pain and Swelling - Putting Out the Fire Natural Relief for Soreness, Pain and Swelling - Putting Out the Fire
Complete and Natural Menopause Relief Complete and Natural Menopause Relief
Milk Thistle: Trusted Support for Health & Healing in a Toxic World Milk Thistle: Trusted Support for Health & Healing in a Toxic World

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map